文献速递白血病造血干细胞移植与细胞治疗

新型靶向与细胞治疗在伴Ph样融合的复发难治性成人急性淋巴细胞白血病中诱导高缓解率并成功过渡至移植

High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Philadelphia-like fusions.
PubMed 文献 · Am J Hematol · 2023-03-16

单中心回顾性分析96例伴Ph样融合的复发难治性B-ALL成人患者,接受149次新型挽救方案(贝林妥欧单抗83次、奥加伊妥珠单抗36次、CD19CAR T细胞30次)。贝林妥欧单抗、奥加伊妥珠单抗和CD19CAR T的完全缓解/不完全血液学恢复的完全缓解率分别为63%、72%和90%,相应缓解者中分别有50%、50%和44%接受异基因造血干细胞移植巩固。多变量分析中,新型治疗类型和预处理骨髓原始细胞比例预测缓解率,融合亚型、预处理骨髓原始细胞比例和缓解后异基因造血干细胞移植巩固影响无事件生存。

要点

  • 贝林妥欧单抗、奥加伊妥珠单抗和CD19CAR T的完全缓解/不完全血液学恢复的完全缓解率分别为63%、72%和90%。
  • 缓解者中分别有50%、50%和44%接受异基因造血干细胞移植巩固。
  • 融合亚型、预处理骨髓原始细胞比例和缓解后异基因造血干细胞移植巩固影响无事件生存。

核心结论

  • 新型疗法在复发难治性Ph样急性淋巴细胞白血病患者中可有效诱导高缓解率,并成功将缓解者过渡至异基因造血干细胞移植。

研究设计与样本

  • 单中心回顾性分析,纳入96例伴Ph样融合的复发难治性B-ALL成人患者,共接受149次新型挽救方案(贝林妥欧单抗83次、奥加伊妥珠单抗36次、CD19CAR T细胞30次)。

主要发现

  • 首次新型挽救治疗的中位年龄为36岁(范围18-71岁)。
  • Ph样融合类型包括IGH::CRLF2(48例)、P2RY8::CRLF2(26例)、JAK2(9例)、ABL类(8例)、EPOR::IGH(4例)和ETV6::NTRK2(1例)。
  • CD19CAR T细胞较贝林妥欧单抗和奥加伊妥珠单抗更晚用于治疗进程(p < .001),且更常用于异基因造血干细胞移植后复发者(p = .002)。
  • 贝林妥欧单抗较奥加伊妥珠单抗和CAR T细胞用于更年长患者(p = .004)。
  • 贝林妥欧单抗、奥加伊妥珠单抗和CD19CAR T的完全缓解/不完全血液学恢复的完全缓解率分别为63%、72%和90%,缓解者中分别有50%、50%和44%接受异基因造血干细胞移植巩固。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Philadelphia (Ph)-like acute lymphoblastic leukemia (ALL) is associated with a poor response to standard chemotherapy. However, outcomes with novel antibody and cellular therapies in relapsed/refractory (r/r) Ph-like ALL are largely unknown. We conducted a single-center retrospective analysis of adult patients (n = 96) with r/r B-ALL and fusions associated with Ph-like who received novel salvage therapies. Patients were treated with 149 individual novel regimens (blinatumomab = 83, inotuzumab ozogamicin [InO] = 36, and CD19CAR T cells = 30). The median age at first novel salvage therapy was 36 years (range; 18-71). Ph-like fusions were IGH::CRLF2 (n = 48), P2RY8::CRLF2 (n = 26), JAK2 (n = 9), ABL-class (n = 8), EPOR::IGH (n = 4) and ETV6::NTRK2 (n = 1). CD19CAR T cells were administered later in the course of therapy compared to blinatumomab and InO (p < .001) and more frequently in recipients who relapsed after allogeneic hematopoietic cell transplantation (alloHCT) (p = .002). Blinatumomab was administered at an older age compared to InO and CAR T-cells (p = .004). The complete remission (CR)/CR with incomplete hematologic recovery (CRi) rates were 63%, 72%, and 90% following blinatumomab, InO and CD19CAR, respectively, among which 50%, 50%, and 44% of responders underwent consolidation with alloHCT, respectively. In multivariable analysis, the type of novel therapy (p = .044) and pretreatment marrow blasts (p = .006) predicted the CR/CRi rate, while the Ph-like fusion subtype (p = .016), pretreatment marrow blasts (p = .022) and post-response consolidation with alloHCT (p < .001) influenced event-free survival. In conclusion, novel therapies are effective in inducing high remission rates in patients with r/r Ph-like ALL and successfully transitioning the responders to alloHCT.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Aldoss I, Afkhami M, Yang D, et al. High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Philadelphia-like fusions. Am J Hematol. 2023. PMID: 36880203. doi:10.1002/ajh.26908

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。